![]() |
|
|
EPA Licenses Simulations Plus' ADMET Predictor Software to Identify Chemical Hazards
U.S. EPA Licenses Simulations Plus' ADMET Predictor(TM) SoftwareAgency Licenses Both Toxicity and New Enslein Metabolism ModulesSimulations Plus, Inc. (NASDAQ: SLP - News), a leading provider of software for pharmaceutical discovery and development, announced that it has received a purchase order from the U.S. Environmental Protection Agency for its ADMET Predictor™ software. Ron Creeley, vice president of marketing and sales for Simulations Plus, said: "This is our first software license from the EPA. We’re especially pleased that they have recognized the value of ADMET Predictor’s Toxicity Module and our new Enslein Metabolism Module in their work." So it’s important for both the EPA, the chemical industry, and drug manufacturers to consider not only how new molecules accomplish their designed purpose, but also how the environment could be affected if and when they get into our air or water. Dr. Robert Fraczkiewicz, team leader for Simulations Plus’ ADMET Cheminformatics team and product manager for ADMET Predictor, added: "Because the EPA generated the data for a number of our toxicity predictions, it is especially appropriate that it has now come full circle in the form of high quality predictive models for them to use in their ongoing efforts to protect our environment. Good models begin with good data, and the investment made by the EPA over the years in measuring various types of toxicities is now providing an additional return in the form of high quality toxicity predictions for new molecules. "ADMET Predictor will allow the EPA to predict a number of potential toxicities for industry chemicals, agricultural chemicals, and drug molecules plus excipients. "Additionally, even if a chemical in question is not toxic, its metabolites might be. This is where ADMET Predictor’s Enslein Metabolism Module becomes useful in recognizing which of the human cytochromes P450 will metabolize the chemical and how fast this will happen," he explained. About Simulations Plus, Inc. Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery and development software, which is licensed to and used in the conduct of drug research by pharmaceutical, biotechnology, and drug delivery companies worldwide. The Company has two other businesses, Words+, Inc. and FutureLab™, which are based on its proprietary software technologies. Simulations Plus, Inc., is headquartered in Southern California and trades on the NASDAQ under the symbol “SLP.” For more information, visit our Web site at www.simulations-plus.com.
|
||||||||||
|
||||||||||
|
|
|||||||||
CONSUMERS | Backyard Nature | Senior Health | MultiMedia Marketing | Marketing | |